<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Endocrinol Metab</journal-id><journal-id journal-id-type="pmc-domain-id">561</journal-id><journal-id journal-id-type="pmc-domain">jcem</journal-id><journal-id journal-id-type="publisher-id">jcem</journal-id><journal-title-group><journal-title>The Journal of Clinical Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">0021-972X</issn><issn pub-type="epub">1945-7197</issn><publisher><publisher-name>The Endocrine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12187182</article-id><article-id pub-id-type="pmcid-ver">PMC12187182.1</article-id><article-id pub-id-type="pmcaid">12187182</article-id><article-id pub-id-type="pmcaiid">12187182</article-id><article-id pub-id-type="pmid">39418352</article-id><article-id pub-id-type="doi">10.1210/clinem/dgae734</article-id><article-id pub-id-type="publisher-id">dgae734</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00250</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0304-4044</contrib-id><name name-style="western"><surname>Bhat</surname><given-names initials="SZ">Salman Zahoor</given-names></name><aff>
<institution>Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="J">Jiajun</given-names></name><aff>
<institution>Department of Pediatrics, Biostatistics, Epidemiology and Data Management (BEAD) Core, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21224</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5482-6620</contrib-id><name name-style="western"><surname>Perin</surname><given-names initials="J">Jamie</given-names></name><aff>
<institution>Department of International Health, Johns Hopkins Bloomberg School of Public Health</institution>, <addr-line>Baltimore, MD 21205</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="K">Kunbo</given-names></name><aff>
<institution>Department of Applied Mathematics and Statistics, Johns Hopkins University</institution>, <addr-line>Baltimore, MD 21218</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Robinson</surname><given-names initials="ML">Matthew L</given-names></name><aff>
<institution>Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garibaldi</surname><given-names initials="BT">Brian T</given-names></name><aff>
<institution>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0210-655X</contrib-id><name name-style="western"><surname>Mathioudakis</surname><given-names initials="N">Nestoras</given-names></name><aff>
<institution>Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff><xref rid="dgae734-cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="dgae734-cor1"><bold>Correspondence</bold>: Nestoras Mathioudakis, MD, MHS, Division of Endocrinology, Diabetes &amp; Metabolism, Johns Hopkins University School of Medicine, 1830 E. Monument Street, Suite 333, Baltimore, MD 21287, USA. Email: <email>nmathio1@jh.edu</email>.</corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-10-17"><day>17</day><month>10</month><year>2024</year></pub-date><volume>110</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">491309</issue-id><fpage>1846</fpage><lpage>1853</lpage><history><date date-type="received"><day>16</day><month>7</month><year>2024</year></date><date date-type="editorial-decision"><day>14</day><month>10</month><year>2024</year></date><date date-type="corrected-typeset"><day>28</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-25 16:25:40.200"><day>25</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dgae734.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dgae734.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Patients with diabetes have higher mortality from COVID-19 compared to the general population. Dexamethasone, a potent glucocorticoid used for moderate to severe COVID-19, can worsen hyperglycemia in patients with diabetes, potentially leading to worse outcomes. The efficacy and safety of use of dexamethasone for COVID-19 in patients with diabetes needs further evaluation.</p></sec><sec id="s2"><title>Objective</title><p>The study aimed to assess the efficacy and safety of dexamethasone in patients with diabetes hospitalized for COVID-19 infection.</p></sec><sec id="s3"><title>Design</title><p>This retrospective study analyzed data from 5 hospitals in the Johns Hopkins Health System collected between March 3, 2020, and June 25, 2022. Propensity score matching was applied to a cohort of patients with diabetes who received dexamethasone and those who did not (controls), and outcomes were compared using Cox proportional hazards regression models.</p></sec><sec id="s4"><title>Outcomes</title><p>The primary outcome was time to death within 28 days. The secondary outcome was time to clinical improvement. Additional outcomes included the incidence of hyperglycemic emergencies and subgroup analysis of primary outcomes by clinical severity.</p></sec><sec id="s5"><title>Results</title><p>Out of 10,329 patients admitted for COVID-19, 3679 had diabetes, and 2361 met the inclusion criteria. After propensity score matching, 529 patients were analyzed in each group. Survival rates between the dexamethasone and control groups during the 0- to 6-day and 7- to 28-day periods and time to clinical improvement at 28 days did not differ significantly. There was no difference in the incidence of diabetic ketoacidosis or hyperosmolar hyperglycemic state between the groups.</p></sec><sec id="s6"><title>Conclusion</title><p>Dexamethasone treatment did not significantly improve survival or time to clinical improvement in patients with diabetes and COVID-19 infection. Further prospective studies are needed to confirm these findings and determine potential mechanisms.</p></sec></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID</kwd><kwd>glucocorticoids</kwd><kwd>steroids</kwd><kwd>diabetes</kwd><kwd>hyperglycemia</kwd><kwd>diabetic ketoacidosis</kwd></kwd-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The COVID-19 pandemic has resulted in more than 7 million deaths worldwide (<xref rid="dgae734-B1" ref-type="bibr">1</xref>). Patients with diabetes face a significantly higher risk of adverse clinical outcomes; they are twice as likely to develop severe respiratory disease and die from COVID-19 compared to patients without diabetes (<xref rid="dgae734-B2" ref-type="bibr">2-4</xref>). The risk is even greater for those with microvascular and macrovascular complications resulting from diabetes (<xref rid="dgae734-B5" ref-type="bibr">5</xref>, <xref rid="dgae734-B6" ref-type="bibr">6</xref>). Furthermore, the rates and clinical outcomes of diabetic ketoacidosis (DKA) are worse in COVID-19-infected patients (<xref rid="dgae734-B7" ref-type="bibr">7-10</xref>). Hyperglycemia exacerbates these risks by promoting SARS-COV-2 viral proliferation and adversely affecting pulmonary function. This occurs through an enhanced proinflammatory response, reactive oxygen species generation, and pulmonary vascular dysfunction (<xref rid="dgae734-B11" ref-type="bibr">11-13</xref>). Hyperglycemia weakens the antiviral immune response by impairing the recruitment and function of natural killer and CD-4/CD-8 T-cells (<xref rid="dgae734-B14" ref-type="bibr">14</xref>).</p><p>Corticosteroids emerged as one of the early therapies demonstrating clinical benefit in COVID-19-infected patients requiring oxygen therapy. The RECOVERY trial, along with other studies and meta-analyses, confirmed the efficacy of glucocorticoids, leading to recommendations for dexamethasone in the inpatient management of COVID-19 infection (<xref rid="dgae734-B15" ref-type="bibr">15-17</xref>). The RECOVERY trial was a large-scale prospective randomized controlled trial studying the use of 6&#8197;mg/day of dexamethasone for 10 days for the management of COVID-19 infection. It reported a 17% reduction in 28-day mortality among SARS-COV-2-infected patients requiring oxygen supplementation [22.9% in the dexamethasone group and 25.7% in the control group; 95% confidence interval (CI) .75 to .93; <italic toggle="yes">P</italic> &lt; .001] (<xref rid="dgae734-B15" ref-type="bibr">15</xref>).</p><p>Exacerbation of hyperglycemia in patients with diabetes and the development of new-onset hyperglycemia in patients without diabetes is one of the common side effects of dexamethasone and other potent glucocorticoids (<xref rid="dgae734-B18" ref-type="bibr">18</xref>). Mechanisms of glucocorticoid-induced hyperglycemia include negative postreceptor effects on insulin action, resulting in insulin resistance, increased hepatic gluconeogenesis, and decreased tissue glucose uptake by skeletal muscle and adipose tissue by inhibition of glucose transporter type 4 expression (<xref rid="dgae734-B19" ref-type="bibr">19-22</xref>). Glucocorticoids result in increased glucose production from the liver by stimulating rate-limiting enzymes of hepatic gluconeogenesis and increasing concentrations of gluconeogenic substrates (<xref rid="dgae734-B23" ref-type="bibr">23</xref>). Glucocorticoids impact beta cell function directly by affecting the beta cell lifespan and secretory capacity (<xref rid="dgae734-B24" ref-type="bibr">24-27</xref>). Consequently, this insulin resistance and beta cell dysfunction often lead to substantially increased insulin requirements among insulin-treated patients (<xref rid="dgae734-B28" ref-type="bibr">28</xref>).</p><p>Uncontrolled hyperglycemia in patients with COVID-19 infection is associated with a higher likelihood of mechanical ventilation and higher in-hospital mortality (<xref rid="dgae734-B29" ref-type="bibr">29</xref>, <xref rid="dgae734-B30" ref-type="bibr">30</xref>). Thus, the clinical benefits of dexamethasone in treating COVID-19 in patients with diabetes are not clear-cut and may be offset by its adverse effects on glycemic control. Accordingly, we conducted this study to evaluate the efficacy and safety of dexamethasone for treating COVID-19 in patients with diabetes.</p><sec sec-type="materials|methods" id="dgae734-s1"><title>Materials and Methods</title><sec id="dgae734-s1.1"><title>Study Design and Data Sources</title><p>This retrospective cohort study used deidentified data from the Johns Hopkins CROWN database, a registry comprised of electronic medical record data and supplemented by other data sources such as physiologic device monitoring systems of patients. Hosted on the Precision Medicine Analytics Platform, Johns Hopkins CROWN integrates data from 5 hospitals within the Johns Hopkins Health System for the study of COVID-19 (<xref rid="dgae734-B31" ref-type="bibr">31</xref>). The database includes records of patients admitted with symptomatic COVID-19 infection confirmed by SARS-COV-2 polymerase chain reaction testing from nasal or oropharyngeal samples and required hospitalization.</p><p>The research question, methodology, and data access received approval from the Johns Hopkins University School of Medicine Institutional Review Board, which also waived the requirement for informed consent due to the minimal risk associated with the study design. Administration of dexamethasone followed World Health Organization (WHO) and Food and Drug Administration guidelines, as recommended by the RECOVERY trial findings (<xref rid="dgae734-B15" ref-type="bibr">15</xref>).</p></sec><sec id="dgae734-s1.2"><title>Study Cohort/Inclusion/Exclusion Criteria</title><p>Patients admitted to the Johns Hopkins Health System for the treatment of COVID-19 infection during the period from March 4, 2020, to June 25, 2022, were considered for this study. Eligibility was based on a diagnosis of diabetes identified using International Classification of Diseases, Tenth Revision codes (E10, E11, E12, E13) or a hemoglobin A1C level consistent with diabetes (A1C &#8805; 6.5%) either during hospitalization or within 90 days prior. The primary exposure of interest was the administration of oral or IV dexamethasone at a dosage of 6&#8197;mg/day in patients who required inpatient management of COVID-19 infection, defined by an oxygen saturation &#8804;94% on room air or the need for supplemental oxygen or mechanical ventilation to maintain an SpO2 &gt; 94% for at least 1 hour. Exclusions were applied to patients discharged or deceased within 24&#8197;hours after hospital admission, those treated with dexamethasone dosages other than 6&#8197;mg/day, those with incomplete clinical data, and patients admitted before May 27, 2020, when dexamethasone was not yet a primary treatment for COVID-19. The study aimed to compare outcomes between patients who received dexamethasone and those who did not, after applying inclusion and exclusion criteria.</p></sec><sec id="dgae734-s1.3"><title>Statistical Analysis</title><p>Descriptive statistics were used to characterize the study population. The Kruskal&#8211;Wallis test assessed continuous variables, while the Fisher test evaluated categorical variables. We performed propensity score matching using both time-independent and time-dependent variables to create clinically comparable pairs of patients, 1 receiving dexamethasone and the other not (<xref rid="dgae734-B32" ref-type="bibr">32</xref>). This matching addressed the nonrandomized assignment of dexamethasone and variable timing of its administration (<xref rid="dgae734-B33" ref-type="bibr">33</xref>).</p><p>We calculated the propensity scores using a time-dependent Cox regression model, with the time to dexamethasone receipt as the outcome. For matching, we employed a sequential 1:1 greedy algorithm without replacement from hospital day 0, using a threshold of less than 0.2 times the SD of hazard components for the propensity score difference (<xref rid="dgae734-B33" ref-type="bibr">33</xref>).</p><p>The first day of dexamethasone administration was defined as the index day. Time-dependent variables were aggregated daily, recording the mean value for each variable per day. The WHO severity score was computed every 6&#8197;hours, recording the highest score of the day for each patient. Missing laboratory data were imputed using the last observation carried forward method if the observation was within 3 days prior; other missing values were addressed with multiple imputation using the chained equations method (<xref rid="dgae734-B34" ref-type="bibr">34</xref>).</p><p>Cox proportional hazards regression models, incorporating demographic, clinical, and laboratory variables, analyzed the association between dexamethasone use and study outcomes (<xref rid="dgae734-B32" ref-type="bibr">32</xref>). Further details on matching processes and variables are provided in the Supplemental Data (<xref rid="dgae734-B32" ref-type="bibr">32</xref>).</p></sec><sec id="dgae734-s1.4"><title>Outcomes</title><p>The primary outcome was the time to death from the first day of dexamethasone treatment. The secondary outcome was time to clinical improvement from the start of treatment, defined as either hospital discharge without deterioration of the WHO severity score or a reduction of at least 2 points in the WHO severity score during hospitalization up to the maximum follow-up period. We censored the primary outcome data on the lesser of the last day of follow-up or 28 days postmatching. Patients discharged alive were censored at 28 days to accommodate for the competing risks of death and discharge.</p><p>Further secondary outcomes included the time to death and clinical improvement stratified by initial WHO severity score: mild/moderate (scores 3-4) and severe/critical (scores 5-7). Additionally, we examined the incidence of DKA and hyperglycemic hyperosmolar state (HHS) in the dexamethasone group compared to the control group (<xref rid="dgae734-B32" ref-type="bibr">32</xref>).</p></sec></sec><sec sec-type="results" id="dgae734-s2"><title>Results</title><sec id="dgae734-s2.1"><title>Patient Characteristics</title><p>
<xref rid="dgae734-F1" ref-type="fig">Figure 1</xref> provides the study flowchart. Among 10 329 patients admitted with COVID-19 infection during the study period, we identified 3679 patients with diabetes. After applying the eligibility criteria, the study analyzed data from 2631 patients with diabetes. Among these patients, 1528 received dexamethasone, while 1103 patients did not. The median duration of dexamethasone use was 6 days, the median time from admission to the first dose of dexamethasone was 0.76 days, and median duration between doses was 0.99 days.</p><fig position="float" id="dgae734-F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Study flowchart describing patients included in the analysis. *Note: 445 patients who were admitted before May 27, 2020, were removed as dexamethasone was not considered a standard-of-care treatment option for COVID-19 infection prior to this date.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dgae734f1.jpg"/></fig><p>The final study cohort for primary analysis was obtained after propensity score matching had 529 patients in the dexamethasone group and 529 patients in the control group. <xref rid="dgae734-T1" ref-type="table">Table 1</xref> shows the baseline characteristics of the study population. Demographics and baseline characteristics were similar between the groups, with a median age of around 65 years and a balanced distribution across sexes and racial groups. The median length of stay and glycemic control parameters (A1C and baseline blood glucose) were also comparable between the 2 groups. The median glucose [interquartile range (IQR)] was 230&#8197;mg/dL (168-295) in the treatment group and 185&#8197;mg/dL (131, 277) in the control group, with significantly higher levels in the treatment group (<italic toggle="yes">P</italic> &lt; 0.001).</p><table-wrap position="float" id="dgae734-T1" orientation="portrait"><label>Table 1.</label><caption><p>Baseline characteristics: unmatched and matched cohorts</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">All unmatched patients</th><th align="left" colspan="3" rowspan="1">Propensity score matched patients</th></tr><tr><td align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Dexamethasone</th><th align="left" rowspan="1" colspan="1">Control</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th><th align="left" rowspan="1" colspan="1">Dexamethasone</th><th align="left" rowspan="1" colspan="1">Control</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">n = 1528</th><th rowspan="1" colspan="1">n = 1103</th><td rowspan="1" colspan="1"/><th rowspan="1" colspan="1">n = 529</th><th rowspan="1" colspan="1">n = 529</th><td rowspan="1" colspan="1"/></tr></thead><tbody><tr><td rowspan="1" colspan="1">&#8195;Sex, number (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Male</td><td rowspan="1" colspan="1">810 (53.0)</td><td rowspan="1" colspan="1">555 (50.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">288 (54.4)</td><td rowspan="1" colspan="1">273 (51.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Female</td><td rowspan="1" colspan="1">718 (47.0)</td><td rowspan="1" colspan="1">548 (49.7)</td><td rowspan="1" colspan="1">.179</td><td rowspan="1" colspan="1">241 (45.6)</td><td rowspan="1" colspan="1">256 (48.4)</td><td rowspan="1" colspan="1">.388</td></tr><tr><td rowspan="1" colspan="1">&#8195;Ethnicity, number (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Not Hispanic</td><td rowspan="1" colspan="1">1354 (88.6)</td><td rowspan="1" colspan="1">1004 (91.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">474 (89.6)</td><td rowspan="1" colspan="1">479 (90.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Hispanic</td><td rowspan="1" colspan="1">174 (11.4)</td><td rowspan="1" colspan="1">99 (9.0)</td><td rowspan="1" colspan="1">.052</td><td rowspan="1" colspan="1">55 (10.4)</td><td rowspan="1" colspan="1">50 (9.5)</td><td rowspan="1" colspan="1">.681</td></tr><tr><td rowspan="1" colspan="1">&#8195;Race, number (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Black</td><td rowspan="1" colspan="1">608 (39.8)</td><td rowspan="1" colspan="1">515 (46.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">217 (41.0)</td><td rowspan="1" colspan="1">222 (42.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;White</td><td rowspan="1" colspan="1">593 (38.8)</td><td rowspan="1" colspan="1">415 (37.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">202 (38.2)</td><td rowspan="1" colspan="1">218 (41.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Other</td><td rowspan="1" colspan="1">216 (14.1)</td><td rowspan="1" colspan="1">125 (11.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">69 (13.0)</td><td rowspan="1" colspan="1">68 (12.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Asian</td><td rowspan="1" colspan="1">111 (7.3)</td><td rowspan="1" colspan="1">48 (4.4)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">41 (7.8)</td><td rowspan="1" colspan="1">21 (4.0)</td><td rowspan="1" colspan="1">.067</td></tr><tr><td rowspan="1" colspan="1">&#8195;Age, y</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mean (SD)</td><td rowspan="1" colspan="1">65.7 (14.8)</td><td rowspan="1" colspan="1">63.3 (16.6)</td><td rowspan="1" colspan="1">.005</td><td rowspan="1" colspan="1">64.5 (16.0)</td><td rowspan="1" colspan="1">64.9 (15.3)</td><td rowspan="1" colspan="1">.407</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Median [IQR]</td><td rowspan="1" colspan="1">66.0 [56.0, 76.0]</td><td rowspan="1" colspan="1">65.0 [53.0, 75.0]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">65.0 [54.0, 76.0]</td><td rowspan="1" colspan="1">66.0 [56.0, 77.0]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Diabetes type</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Type 2</td><td rowspan="1" colspan="1">1516 (99.2)</td><td rowspan="1" colspan="1">1066 (96.6)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">524 (99.1)</td><td rowspan="1" colspan="1">513 (97.0)</td><td rowspan="1" colspan="1">.025</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Type 1</td><td rowspan="1" colspan="1">12 (0.8)</td><td rowspan="1" colspan="1">37 (3.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5 (0.9)</td><td rowspan="1" colspan="1">16 (3.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Code status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Full code</td><td rowspan="1" colspan="1">1429 (93.5)</td><td rowspan="1" colspan="1">1042 (94.5)</td><td rowspan="1" colspan="1">.323</td><td rowspan="1" colspan="1">493 (93.2)</td><td rowspan="1" colspan="1">497 (94.0)</td><td rowspan="1" colspan="1">.707</td></tr><tr><td rowspan="1" colspan="1">&#8195;DNR/DNI</td><td rowspan="1" colspan="1">99 (6.5)</td><td rowspan="1" colspan="1">61 (5.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">36 (6.8)</td><td rowspan="1" colspan="1">32 (6.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Length of stay, days</td><td rowspan="1" colspan="1">8.00 [5.00, 15.0]</td><td rowspan="1" colspan="1">5.00 [3.00, 9.00]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">7.00 [5.00, 11.0]</td><td rowspan="1" colspan="1">7.00 [4.00, 12.0]</td><td rowspan="1" colspan="1">.337</td></tr><tr><td rowspan="1" colspan="1">In-hospital mortality, number (%)</td><td rowspan="1" colspan="1">203 (13.3)</td><td rowspan="1" colspan="1">43 (3.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">57 (10.8)</td><td rowspan="1" colspan="1">38 (7.2)</td><td rowspan="1" colspan="1">.052</td></tr><tr><td rowspan="1" colspan="1">Vital signs, median [IQR]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Temperature, &#176;F</td><td rowspan="1" colspan="1">98.6 [97.9, 99.8]</td><td rowspan="1" colspan="1">98.2 [97.6, 98.8]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">98.5 [97.8, 99.5]</td><td rowspan="1" colspan="1">98.2 [97.7, 98.8]</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;SpO<sub>2</sub>, %</td><td rowspan="1" colspan="1">95.0 [92.0, 97.0]</td><td rowspan="1" colspan="1">98.0 [96.0, 99.0]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">95.0 [93.0, 98.0]</td><td rowspan="1" colspan="1">97.0 [95.0, 99.0]</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Pulse, beats per min</td><td rowspan="1" colspan="1">95.0 [82.0, 108]</td><td rowspan="1" colspan="1">91.0 [78.0, 105]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">96.0 [83.0, 110]</td><td rowspan="1" colspan="1">91.0 [77.0, 106]</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Respiratory, breaths per min</td><td rowspan="1" colspan="1">20.0 [18.0, 24.0]</td><td rowspan="1" colspan="1">18.0 [16.0, 20.0]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">20.0 [18.0, 24.0]</td><td rowspan="1" colspan="1">18.0 [17.0, 20.0]</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;SBP, mm Hg</td><td rowspan="1" colspan="1">132 [117, 149]</td><td rowspan="1" colspan="1">135 [118, 154]</td><td rowspan="1" colspan="1">.007</td><td rowspan="1" colspan="1">132 [117, 150]</td><td rowspan="1" colspan="1">134 [116, 153]</td><td rowspan="1" colspan="1">.629</td></tr><tr><td rowspan="1" colspan="1">&#8195;DBP, mm Hg</td><td rowspan="1" colspan="1">74.0 [64.0, 84.0]</td><td rowspan="1" colspan="1">75.0 [65.0, 86.0]</td><td rowspan="1" colspan="1">.018</td><td rowspan="1" colspan="1">75.0 [65.0, 85.0]</td><td rowspan="1" colspan="1">74.0 [64.0, 86.0]</td><td rowspan="1" colspan="1">.822</td></tr><tr><td rowspan="1" colspan="1">&#8195;BMI, kg/m2</td><td rowspan="1" colspan="1">31.0 [27.0, 37.0]</td><td rowspan="1" colspan="1">28.0 [24.0, 34.0]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">30.0 [26.0, 36.0]</td><td rowspan="1" colspan="1">28.0 [24.0, 35.0]</td><td rowspan="1" colspan="1">.031</td></tr><tr><td rowspan="1" colspan="1">Glycemic parameters, median [IQR]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Blood glucose, mg/dL</td><td rowspan="1" colspan="1">170 [125, 248]</td><td rowspan="1" colspan="1">159 [117, 244]</td><td rowspan="1" colspan="1">.011</td><td rowspan="1" colspan="1">166 [124, 251]</td><td rowspan="1" colspan="1">162 [119, 243]</td><td rowspan="1" colspan="1">.157</td></tr><tr><td rowspan="1" colspan="1">&#8195;HbA1C, %</td><td rowspan="1" colspan="1">7.50 [6.70, 8.90]</td><td rowspan="1" colspan="1">7.60 [6.60, 9.40]</td><td rowspan="1" colspan="1">.426</td><td rowspan="1" colspan="1">7.30 [6.60, 8.95]</td><td rowspan="1" colspan="1">7.50 [6.60, 9.10]</td><td rowspan="1" colspan="1">.546</td></tr><tr><td rowspan="1" colspan="1">Lab values, median [IQR]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;WBC count, 103/&#956;L</td><td rowspan="1" colspan="1">7.06 [5.19, 9.65]</td><td rowspan="1" colspan="1">7.82 [5.54, 11.2]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">7.44 [5.50, 10.5]</td><td rowspan="1" colspan="1">7.63 [5.41, 11.8]</td><td rowspan="1" colspan="1">.24</td></tr><tr><td rowspan="1" colspan="1">&#8195;Platelet count, 103/&#956;L</td><td rowspan="1" colspan="1">203 [155, 262]</td><td rowspan="1" colspan="1">231 [170, 304]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">216 [158, 283]</td><td rowspan="1" colspan="1">222 [162, 293]</td><td rowspan="1" colspan="1">.272</td></tr><tr><td rowspan="1" colspan="1">&#8195;D-dimer, &#956;g/mL</td><td rowspan="1" colspan="1">1.03 [0.620, 1.91]</td><td rowspan="1" colspan="1">1.21 [0.610, 2.42]</td><td rowspan="1" colspan="1">.038</td><td rowspan="1" colspan="1">1.07 [0.620, 1.98]</td><td rowspan="1" colspan="1">1.39 [0.670, 3.12]</td><td rowspan="1" colspan="1">.002</td></tr><tr><td rowspan="1" colspan="1">&#8195;Ferritin, &#956;g/L</td><td rowspan="1" colspan="1">565 [282, 1060]</td><td rowspan="1" colspan="1">388 [140, 845]</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">502 [245, 1040]</td><td rowspan="1" colspan="1">460 [172, 946]</td><td rowspan="1" colspan="1">.087</td></tr><tr><td rowspan="1" colspan="1">Comorbidities, number (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Hypertension</td><td rowspan="1" colspan="1">1362 (89.1)</td><td rowspan="1" colspan="1">973 (88.2)</td><td rowspan="1" colspan="1">.492</td><td rowspan="1" colspan="1">472 (89.2)</td><td rowspan="1" colspan="1">485 (91.7)</td><td rowspan="1" colspan="1">.209</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diabetic nephropathy</td><td rowspan="1" colspan="1">634 (41.5)</td><td rowspan="1" colspan="1">521 (47.2)</td><td rowspan="1" colspan="1">.004</td><td rowspan="1" colspan="1">209 (39.5)</td><td rowspan="1" colspan="1">266 (50.3)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diabetic retinopathy</td><td rowspan="1" colspan="1">254 (16.6)</td><td rowspan="1" colspan="1">239 (21.7)</td><td rowspan="1" colspan="1">.001</td><td rowspan="1" colspan="1">85 (16.1)</td><td rowspan="1" colspan="1">114 (21.6)</td><td rowspan="1" colspan="1">.027</td></tr><tr><td rowspan="1" colspan="1">&#8195;Coronary artery disease</td><td rowspan="1" colspan="1">657 (43.0)</td><td rowspan="1" colspan="1">537 (48.7)</td><td rowspan="1" colspan="1">.004</td><td rowspan="1" colspan="1">228 (43.1)</td><td rowspan="1" colspan="1">283 (53.5)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Heart failure</td><td rowspan="1" colspan="1">567 (37.1)</td><td rowspan="1" colspan="1">440 (39.9)</td><td rowspan="1" colspan="1">.155</td><td rowspan="1" colspan="1">202 (38.2)</td><td rowspan="1" colspan="1">234 (44.2)</td><td rowspan="1" colspan="1">.053</td></tr><tr><td rowspan="1" colspan="1">&#8195;Stroke</td><td rowspan="1" colspan="1">257 (16.8)</td><td rowspan="1" colspan="1">216 (19.6)</td><td rowspan="1" colspan="1">.072</td><td rowspan="1" colspan="1">93 (17.6)</td><td rowspan="1" colspan="1">109 (20.6)</td><td rowspan="1" colspan="1">.241</td></tr><tr><td rowspan="1" colspan="1">&#8195;Chronic lung disease</td><td rowspan="1" colspan="1">324 (21.2)</td><td rowspan="1" colspan="1">201 (18.2)</td><td rowspan="1" colspan="1">.06</td><td rowspan="1" colspan="1">94 (17.8)</td><td rowspan="1" colspan="1">116 (21.9)</td><td rowspan="1" colspan="1">.105</td></tr><tr><td rowspan="1" colspan="1">&#8195;Liver disease</td><td rowspan="1" colspan="1">265 (17.3)</td><td rowspan="1" colspan="1">242 (21.9)</td><td rowspan="1" colspan="1">.004</td><td rowspan="1" colspan="1">93 (17.6)</td><td rowspan="1" colspan="1">122 (23.1)</td><td rowspan="1" colspan="1">.032</td></tr><tr><td rowspan="1" colspan="1">&#8195;Malignancy</td><td rowspan="1" colspan="1">100 (6.5)</td><td rowspan="1" colspan="1">105 (9.5)</td><td rowspan="1" colspan="1">.006</td><td rowspan="1" colspan="1">31 (5.9)</td><td rowspan="1" colspan="1">47 (8.9)</td><td rowspan="1" colspan="1">.077</td></tr><tr><td rowspan="1" colspan="1">&#8195;HIV infection</td><td rowspan="1" colspan="1">24 (1.6)</td><td rowspan="1" colspan="1">28 (2.5)</td><td rowspan="1" colspan="1">.089</td><td rowspan="1" colspan="1">8 (1.5)</td><td rowspan="1" colspan="1">12 (2.3)</td><td rowspan="1" colspan="1">.499</td></tr><tr><td rowspan="1" colspan="1">&#8195;Cerebrovascular disease</td><td rowspan="1" colspan="1">350 (22.9)</td><td rowspan="1" colspan="1">309 (28.0)</td><td rowspan="1" colspan="1">.003</td><td rowspan="1" colspan="1">125 (23.6)</td><td rowspan="1" colspan="1">165 (31.2)</td><td rowspan="1" colspan="1">.007</td></tr><tr><td rowspan="1" colspan="1">Medication use, number (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Remdesivir</td><td rowspan="1" colspan="1">1159 (75.9)</td><td rowspan="1" colspan="1">127 (11.5)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">373 (70.5)</td><td rowspan="1" colspan="1">82 (15.5)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Azithromycin</td><td rowspan="1" colspan="1">459 (30.0)</td><td rowspan="1" colspan="1">106 (9.6)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">143 (27.0)</td><td rowspan="1" colspan="1">64 (12.1)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Tocilizumab</td><td rowspan="1" colspan="1">80 (5.2)</td><td rowspan="1" colspan="1">3 (0.3)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">11 (2.1)</td><td rowspan="1" colspan="1">3 (0.6)</td><td rowspan="1" colspan="1">.056</td></tr><tr><td rowspan="1" colspan="1">&#8195;Anticoagulation</td><td rowspan="1" colspan="1">1496 (97.9)</td><td rowspan="1" colspan="1">977 (88.6)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">515 (97.4)</td><td rowspan="1" colspan="1">489 (92.4)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hydroxychloroquine</td><td rowspan="1" colspan="1">7 (0.5)</td><td rowspan="1" colspan="1">2 (0.2)</td><td rowspan="1" colspan="1">.319</td><td rowspan="1" colspan="1">2 (0.4)</td><td rowspan="1" colspan="1">1 (0.2)</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#8195;Statin therapy, outpatient</td><td rowspan="1" colspan="1">933 (61.1)</td><td rowspan="1" colspan="1">665 (60.3)</td><td rowspan="1" colspan="1">.716</td><td rowspan="1" colspan="1">292 (55.2)</td><td rowspan="1" colspan="1">341 (64.5)</td><td rowspan="1" colspan="1">.003</td></tr><tr><td rowspan="1" colspan="1">&#8195;Antihypertensive therapy, outpatient</td><td rowspan="1" colspan="1">1130 (74.0)</td><td rowspan="1" colspan="1">819 (74.3)</td><td rowspan="1" colspan="1">.892</td><td rowspan="1" colspan="1">382 (72.2)</td><td rowspan="1" colspan="1">403 (76.2)</td><td rowspan="1" colspan="1">.16</td></tr><tr><td rowspan="1" colspan="1">&#8195;Insulin therapy, outpatient</td><td rowspan="1" colspan="1">634 (41.5)</td><td rowspan="1" colspan="1">500 (45.3)</td><td rowspan="1" colspan="1">.051</td><td rowspan="1" colspan="1">206 (38.9)</td><td rowspan="1" colspan="1">254 (48.0)</td><td rowspan="1" colspan="1">.004</td></tr><tr><td rowspan="1" colspan="1">Diabetic therapy at home</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No antidiabetic therapy recorded</td><td rowspan="1" colspan="1">381 (24.9)</td><td rowspan="1" colspan="1">279 (25.3)</td><td rowspan="1" colspan="1">.001</td><td rowspan="1" colspan="1">148 (28.0)</td><td rowspan="1" colspan="1">130 (24.6)</td><td rowspan="1" colspan="1">.054</td></tr><tr><td rowspan="1" colspan="1">&#8195;Only insulin therapy</td><td rowspan="1" colspan="1">234 (15.3)</td><td rowspan="1" colspan="1">228 (20.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">88 (16.6)</td><td rowspan="1" colspan="1">115 (21.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Only noninsulin therapy</td><td rowspan="1" colspan="1">477 (31.2)</td><td rowspan="1" colspan="1">313 (28.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">164 (31.0)</td><td rowspan="1" colspan="1">137 (25.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Combined insulin and noninsulin therapy</td><td rowspan="1" colspan="1">400 (26.2)</td><td rowspan="1" colspan="1">272 (24.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">118 (22.3)</td><td rowspan="1" colspan="1">139 (26.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Incomplete data</td><td rowspan="1" colspan="1">36 (2.4)</td><td rowspan="1" colspan="1">11 (1.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11 (2.1)</td><td rowspan="1" colspan="1">8 (1.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Home GLP-1a use</td><td rowspan="1" colspan="1">190 (12.4)</td><td rowspan="1" colspan="1">113 (10.2)</td><td rowspan="1" colspan="1">.084</td><td rowspan="1" colspan="1">61 (11.5)</td><td rowspan="1" colspan="1">58 (11.0)</td><td rowspan="1" colspan="1">.846</td></tr><tr><td rowspan="1" colspan="1">&#8195;Home SGLT-2i use</td><td rowspan="1" colspan="1">173 (11.3)</td><td rowspan="1" colspan="1">127 (11.5)</td><td rowspan="1" colspan="1">.901</td><td rowspan="1" colspan="1">45 (8.5)</td><td rowspan="1" colspan="1">63 (11.9)</td><td rowspan="1" colspan="1">.084</td></tr><tr><td rowspan="1" colspan="1">&#8195;Home metformin use</td><td rowspan="1" colspan="1">687 (45)</td><td rowspan="1" colspan="1">448 (40.6)</td><td rowspan="1" colspan="1">.028</td><td rowspan="1" colspan="1">222 (42)</td><td rowspan="1" colspan="1">206 (38.9)</td><td rowspan="1" colspan="1">.347</td></tr><tr><td rowspan="1" colspan="1">Charlson's Comorbidity Index, number (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;0</td><td rowspan="1" colspan="1">43 (2.8)</td><td rowspan="1" colspan="1">38 (3.4)</td><td rowspan="1" colspan="1">.362</td><td rowspan="1" colspan="1">10 (1.9)</td><td rowspan="1" colspan="1">20 (3.8)</td><td rowspan="1" colspan="1">.094</td></tr><tr><td rowspan="1" colspan="1">&#8195;1-4</td><td rowspan="1" colspan="1">1116 (73.0)</td><td rowspan="1" colspan="1">754 (68.4)</td><td rowspan="1" colspan="1">.01</td><td rowspan="1" colspan="1">382 (72.2)</td><td rowspan="1" colspan="1">342 (64.7)</td><td rowspan="1" colspan="1">.01</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8805;5</td><td rowspan="1" colspan="1">369 (24.2)</td><td rowspan="1" colspan="1">311 (28.2)</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1">137 (25.9)</td><td rowspan="1" colspan="1">167 (31.6)</td><td rowspan="1" colspan="1">0.049</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; DNR/DNI, do not resuscitate/do not intubate; GLP-1a, glucagon-like peptide 1 analog; HbA1C, hemoglobin A1C; IQR, interquartile range; SBP, systolic blood pressure; SGLT-2i, sodium glucose transport-2 inhibitor; WBC, white blood cell.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="dgae734-s3"><title>Study Outcomes</title><sec id="dgae734-s3.1"><title>Time to Death</title><p>The 28-day mortality rates were 8.7% (n = 46) in the dexamethasone group and 6.4% (n = 34) in the control group. The Cox proportional hazard assumption was not maintained across the 28-day period, indicating that the effect of dexamethasone on mortality did not remain constant over time; therefore, in order to adequately assess the temporal effects, the analysis of time-to-death outcomes was segmented into 2 distinct periods: the first covering day 0 to the end of day 6 and the second spanning day 7 to day 28. The segmented analysis of time to death revealed no statistically significant differences between the dexamethasone and control groups during the first period [adjusted hazard ratio (aHR) 0.65; 95% CI .33-1.26, <italic toggle="yes">P</italic> = .20] or the second period (aHR 1.34; 95% CI .64-2.86, <italic toggle="yes">P</italic> = .44) (<xref rid="dgae734-F2" ref-type="fig">Fig. 2</xref>).</p><fig position="float" id="dgae734-F2" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Clinical outcomes. (A-C) Time to death in the 0- to 6-day period in the entire study cohort (A), mild/moderate COVID-19 (B), and severe COVID-19 infection (C), respectively. (D-F) Time to death in the 7- to 28-day period in the entire study cohort (D), mild/moderate COVID-19 (E), and severe COVID-19 infection (F), respectively. (G-I) Cumulative time to clinical improvement in the 0- to 28-day period in the entire study cohort (G), mild/moderate COVID-19 (H), and severe COVID-19 infection (I), respectively.</p><p>Abbreviation: aHR, adjusted hazard ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dgae734f2.jpg"/></fig><p>Further subgroup analysis by disease severity showed no significant differences in time to death between the dexamethasone and control groups for patients with mild/moderate COVID-19 infection during both the first period (aHR 1.71; 95% CI .47-6.23, <italic toggle="yes">P</italic> = .418) and the second period (aHR 3.76, 95% CI .99-14.24, <italic toggle="yes">P</italic> = .052) (<xref rid="dgae734-F2" ref-type="fig">Fig. 2</xref>). Similarly, no significant differences were found for patients with severe/critical COVID-19 infection during the first period (aHR .70; 95% CI .28-1.74, <italic toggle="yes">P</italic> = .44) or the second period (aHR .62; 95% CI .21-1.83, <italic toggle="yes">P</italic> = .39) (<xref rid="dgae734-F2" ref-type="fig">Fig. 2</xref>).</p></sec><sec id="dgae734-s3.2"><title>Time to Clinical Improvement</title><p>Time to clinical improvement was similar in both the dexamethasone group (median 5 days; IQR 2-10 days) and the control group (median 5 days, IQR 3-11 days). At the end of 28 days of follow-up, 84.3% (n = 446) of patients in the dexamethasone group and 89.3% (n = 472) in the control group had achieved clinical improvement. Analysis of time to clinical improvement between 0 and 28 days of follow-up showed no statistically significant benefit in the dexamethasone group compared to the control group (aHR 0.95; 95% CI .83-1.08) (<xref rid="dgae734-F2" ref-type="fig">Fig. 2</xref>). Subgroup analysis by disease severity revealed no significant reduction in time to clinical improvement with dexamethasone in patients with mild/moderate COVID-19 infection (aHR 1.02; 95% CI .87-1.18); however, in patients with severe/critical COVID-19 infection, a significantly slower time to clinical improvement was observed in the dexamethasone group (aHR 0.58; 95% CI .41-.81) (<xref rid="dgae734-F2" ref-type="fig">Fig. 2</xref>).</p></sec><sec id="dgae734-s3.3"><title>DKA</title><p>The incidence of DKA was not statistically different between the treatment and control groups, with 38 patients (7.2%) in the dexamethasone group and 34 patients (6.4%) in the control group developing DKA (<italic toggle="yes">P</italic> = .714). Among patients who developed DKA, all 38 patients in the treatment group had type 2 diabetes, while in the control group, 5 had type 1 diabetes and 29 had type 2 diabetes.</p></sec><sec id="dgae734-s3.4"><title>HHS</title><p>The incidence of HHS was not significantly different between the treatment and control groups, with 26 patients (1.7%) in the treatment group and 19 patients (1.7%) in the control group developing HHS (<italic toggle="yes">P</italic> = 1).</p></sec><sec id="dgae734-s3.5"><title>Sensitivity Analysis</title><p>To address potential confounding from the concurrent use of remdesivir, we performed a sensitivity analysis excluding patients from both the treatment and control groups who had received remdesivir. The time-to-death analysis revealed no statistically significant difference during the first period (aHR 1.26; 95% CI .49-3.23, <italic toggle="yes">P</italic> = .63) but indicated a shorter time in the dexamethasone-treated group during the second period (aHR 3.04; 95% CI 1.08-8.57, <italic toggle="yes">P</italic> = .03) compared to the control group, with neither group receiving remdesivir. The time-to-clinical-improvement models did not converge and are therefore not reported. The rates of DKA and HHS were not significantly different between the dexamethasone-only and control groups in the sensitivity analysis [DKA: 7 (4.5%) vs 25 (5.6%), <italic toggle="yes">P</italic> = .683; HHS: 6 (3.8%) vs 8 (1.8%), <italic toggle="yes">P</italic> = .212].</p></sec></sec><sec sec-type="discussion" id="dgae734-s4"><title>Discussion</title><p>This retrospective cohort study of propensity score-matched patients with diabetes found no statistically significant difference in mortality or clinical improvement between the dexamethasone and control groups. However, among patients with severe/critical COVID-19, dexamethasone use was associated with a slower time to clinical improvement. Additionally, in a sensitivity analysis excluding patients with concurrent use of remdesivir, dexamethasone was associated with a shorter time to death during days 7 to 28 compared to the control group. The incidence of hyperglycemic emergencies, DKA, and HHS, was comparable between the 2 groups.</p><p>The COVID-19 pandemic resulted in a surge of hospitalizations and mortality, with dexamethasone emerging as one of the first treatment options to show beneficial clinical outcomes in hospitalized patients. However, COVID-19 infection impacts individuals differently, and patients with diabetes are more likely to experience worse outcomes (<xref rid="dgae734-B3" ref-type="bibr">3</xref>, <xref rid="dgae734-B35" ref-type="bibr">35</xref>). Regrettably, this cohort also faces a heightened risk of hyperglycemia due to dexamethasone (<xref rid="dgae734-B18" ref-type="bibr">18</xref>, <xref rid="dgae734-B22" ref-type="bibr">22</xref>).</p><p>Our findings offer critical insights for clinicians managing inpatient COVID-19 among patients with diabetes. We observed no overall benefit in reducing mortality or accelerating clinical improvement. Notably, our data indicate that patients with severe/critical COVID-19 who were treated with dexamethasone experienced a significantly slower recovery. The finding of shorter time-to-death with dexamethasone in the sensitivity analysis may reflect an indication bias, where sicker patients were more likely to receive dexamethasone. Given the retrospective nature of our study, we cannot establish causality, and the worse outcomes observed with dexamethasone treatment may be due to residual confounding rather than a direct effect of the medication on recovery rates. These findings underscore the need for further investigation through randomized controlled trials or prospective studies to better understand the implications of dexamethasone treatment in this high-risk patient population.</p><p>Our study is among the first to investigate significant clinical outcomes associated with dexamethasone use for COVID-19 infection in patients with diabetes, contributing a unique perspective to the existing literature. A study by Eng et al, which did not utilize propensity score matching, noted similar benefits of dexamethasone use across 2 different waves of COVID-19 infection in patients with and without diabetes (<xref rid="dgae734-B36" ref-type="bibr">36</xref>). Our study benefits from a diverse and large cohort matched on an extensive set of clinical variables impacting outcomes in COVID-19 infection, including often underrepresented populations at high risk for adverse outcomes.</p><p>However, several limitations must be acknowledged. The retrospective nature of our study introduces the potential for confounding bias due to the nonadjustment of unknown variables. Furthermore, the final propensity score-matched cohort comprised only 40.3% of the unmatched cohort, introducing a potential for selection bias. This was primarily due to challenges in identifying equally sick patients in the control group, as dexamethasone became a standard of care for severe COVID-19 infection. This limitation may have affected the comparability between the groups, potentially leading to an underestimation of effects due to a reduced statistical power. Additionally, the approval of different therapies at various times during the COVID-19 pandemic introduced significant temporal associations in the use of interventions, complicating the interpretation of outcomes due to these secular trends and the concurrent treatments for COVID-19. A majority (70.5%) of the dexamethasone-treated patients in the final cohort also received remdesivir, whereas only 15.5% of patients who did not receive dexamethasone were treated with remdesivir (15.5%). This disparity in treatment could have influenced the clinical outcomes in the respective groups, although we attempted to address this issue with our sensitivity analysis. The WHO severity scale used to assess COVID-19 severity may not accurately reflect the true range of disease severity, as it tends to group diverse scores under the same severity category. Moreover, it lacks the incorporation of inflammatory markers, which predict severity in newer prediction models, and does not include baseline clinical variables known to affect severity and outcomes (<xref rid="dgae734-B2" ref-type="bibr">2</xref>).</p></sec><sec sec-type="conclusions" id="dgae734-s5"><title>Conclusions</title><p>Our study results suggest that the use of dexamethasone for the management of COVID-19 infection in patients with diabetes may not offer significant benefits in terms of survival or clinical improvement compared to patients who did not receive dexamethasone. Furthermore, an association of worse outcomes was observed in severe COVID-19 patients with diabetes who received dexamethasone. Further randomized controlled trials targeting high-risk patients with diabetes and severe COVID-19 are needed to better understand the risk/benefit ratio of dexamethasone use in this population.</p></sec></body><back><ack id="ack1"><title>Acknowledgments</title><p>None.</p></ack><sec id="dgae734-s6"><title>Funding</title><p>This publication was partly supported by the Christopher D. Saudek Diabetes Research Fellowship.</p></sec><sec id="dgae734-s7"><title>Disclosures</title><p>S.Z.B., J.W., J.P., K.W., and N.M. have nothing to disclose. M.L.R. has institutional grants from Fisher Center Discovery Program: Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Johns Hopkins University, Rapid Acceleration of Diagnostics (RADx)/National Institutes of Health (NIH) and Critical Path Institute/FDABG; has consulted for VentureWell/National Institute of Biomedical Imaging and Bioengineering/NIH. B.T.G. has consulted for Gilead and Atea; is on the board of the FDA Pulmonary-Asthma Drug Advisory Committee and Johns Hopkins Internal DSMB for COVID therapeutics; is a board member of Society of Bedside Medicine; has stock options in AriScience; and has received support from Johns Hopkins inHealth for the present manuscript.</p></sec><sec sec-type="data-availability" id="dgae734-s8"><title>Data Availability Statement</title><p>Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.</p></sec><ref-list id="ref1"><title>References</title><ref id="dgae734-B1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>WHO COVID-19 Dashboard</source>. <publisher-name>World Health Organization</publisher-name>, <year>2020</year>.</mixed-citation></ref><ref id="dgae734-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>Q</given-names></string-name></person-group>. <article-title>Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis</article-title>. <source>PLoS One</source>. <year>2021</year>;<volume>16</volume>(<issue>5</issue>):<fpage>e0250602</fpage>.<pub-id pub-id-type="pmid">33939733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0250602</pub-id><pub-id pub-id-type="pmcid">PMC8092779</pub-id></mixed-citation></ref><ref id="dgae734-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barron</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bakhai</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kar</surname> &#160;<given-names>P</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2020</year>;<volume>8</volume>(<issue>10</issue>):<fpage>813</fpage>&#8208;<lpage>822</lpage>.<pub-id pub-id-type="pmid">32798472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30272-2</pub-id><pub-id pub-id-type="pmcid">PMC7426088</pub-id></mixed-citation></ref><ref id="dgae734-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Almeida-Pititto</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dualib</surname> &#160;<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Zajdenverg</surname> &#160;<given-names>L</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis</article-title>. <source>Diabetol Metab Syndr</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>75</fpage>.<pub-id pub-id-type="pmid">32874207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13098-020-00586-4</pub-id><pub-id pub-id-type="pmcid">PMC7456786</pub-id></mixed-citation></ref><ref id="dgae734-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Holman</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Knighton</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kar</surname> &#160;<given-names>P</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2020</year>;<volume>8</volume>(<issue>10</issue>):<fpage>823</fpage>&#8208;<lpage>833</lpage>.<pub-id pub-id-type="pmid">32798471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30271-0</pub-id><pub-id pub-id-type="pmcid">PMC7426091</pub-id></mixed-citation></ref><ref id="dgae734-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McGurnaghan</surname> &#160;<given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Weir</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bishop</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2021</year>;<volume>9</volume>(<issue>2</issue>):<fpage>82</fpage>&#8208;<lpage>93</lpage>.<pub-id pub-id-type="pmid">33357491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30405-8</pub-id><pub-id pub-id-type="pmcid">PMC7832778</pub-id></mixed-citation></ref><ref id="dgae734-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stevens</surname> &#160;<given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Bogun</surname> &#160;<given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>McMahon</surname> &#160;<given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Diabetic ketoacidosis and mortality in COVID-19 infection</article-title>. <source>Diabetes Metab</source>. <year>2021</year>;<volume>47</volume>(<issue>6</issue>):<fpage>101267</fpage>.<pub-id pub-id-type="pmid">34332112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabet.2021.101267</pub-id><pub-id pub-id-type="pmcid">PMC8317499</pub-id></mixed-citation></ref><ref id="dgae734-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goldman</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fink</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>High prevalence of COVID-19-associated diabetic ketoacidosis in UK secondary care</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2020</year>;<volume>166</volume>:<fpage>108291</fpage>.<pub-id pub-id-type="pmid">32615280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2020.108291</pub-id><pub-id pub-id-type="pmcid">PMC7323680</pub-id></mixed-citation></ref><ref id="dgae734-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>COVID-19 infection may cause ketosis and ketoacidosis</article-title>. <source>Diabetes Obes Metab</source>. <year>2020</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1935</fpage>&#8208;<lpage>1941</lpage>.<pub-id pub-id-type="pmid">32314455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.14057</pub-id><pub-id pub-id-type="pmcid">PMC7264681</pub-id></mixed-citation></ref><ref id="dgae734-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lavik</surname> &#160;<given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Ebekozien</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Noor</surname> &#160;<given-names>N</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Trends in type 1 diabetic ketoacidosis during COVID-19 surges at 7 US centers: highest burden on non-hispanic black patients</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2022</year>;<volume>107</volume>(<issue>7</issue>):<fpage>1948</fpage>&#8208;<lpage>1955</lpage>.<pub-id pub-id-type="pmid">35380700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgac158</pub-id><pub-id pub-id-type="pmcid">PMC8992309</pub-id></mixed-citation></ref><ref id="dgae734-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Narasimhulu</surname> &#160;<given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Singla</surname> &#160;<given-names>DK</given-names></string-name></person-group>. <article-title>Mechanisms of COVID-19 pathogenesis in diabetes</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2022</year>;<volume>323</volume>(<issue>3</issue>):<fpage>H403</fpage>&#8208;<lpage>H420</lpage>.<pub-id pub-id-type="pmid">35776683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.00204.2022</pub-id><pub-id pub-id-type="pmcid">PMC9359655</pub-id></mixed-citation></ref><ref id="dgae734-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kolahian</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Leiss</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>N&#252;rnberg</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>Diabetic lung disease: fact or fiction?</article-title> &#160;<source>Rev Endocr Metab Disord</source>. <year>2019</year>;<volume>20</volume>(<issue>3</issue>):<fpage>303</fpage>&#8208;<lpage>319</lpage>.<pub-id pub-id-type="pmid">31637580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11154-019-09516-w</pub-id><pub-id pub-id-type="pmcid">PMC7102037</pub-id></mixed-citation></ref><ref id="dgae734-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Devaraj</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dasu</surname> &#160;<given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Jialal</surname> &#160;<given-names>I</given-names></string-name></person-group>. <article-title>Diabetes is a proinflammatory state: a translational perspective</article-title>. <source>Expert Rev Endocrinol Metab</source>. <year>2010</year>;<volume>5</volume>(<issue>1</issue>):<fpage>19</fpage>&#8208;<lpage>28</lpage>.<pub-id pub-id-type="pmid">20204165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/eem.09.44</pub-id><pub-id pub-id-type="pmcid">PMC2829992</pub-id></mixed-citation></ref><ref id="dgae734-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turk Wensveen</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ga&#353;parini</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Raheli&#263;</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wensveen</surname> &#160;<given-names>FM</given-names></string-name></person-group>. <article-title>Type 2 diabetes and viral infection; cause and effect of disease</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2021</year>;<volume>172</volume>:<fpage>108637</fpage>.<pub-id pub-id-type="pmid">33352263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2020.108637</pub-id><pub-id pub-id-type="pmcid">PMC8050380</pub-id></mixed-citation></ref><ref id="dgae734-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Horby</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname> &#160;<given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Emberson</surname> &#160;<given-names>JR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Dexamethasone in hospitalized patients with COVID-19&#8212;preliminary report</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>384</volume>(<issue>8</issue>):<fpage>693</fpage>&#8208;<lpage>704</lpage>.<pub-id pub-id-type="pmid">32678530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmcid">PMC7383595</pub-id></mixed-citation></ref><ref id="dgae734-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Paassen</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vos</surname> &#160;<given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Hoekstra</surname> &#160;<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Neumann</surname> &#160;<given-names>KMI</given-names></string-name>, <string-name name-style="western"><surname>Boot</surname> &#160;<given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Arbous</surname> &#160;<given-names>SM</given-names></string-name></person-group>. <article-title>Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes</article-title>. <source>Critical Care</source>. <year>2020</year>;<volume>24</volume>(<issue>1</issue>):<fpage>696</fpage>.<pub-id pub-id-type="pmid">33317589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-03400-9</pub-id><pub-id pub-id-type="pmcid">PMC7735177</pub-id></mixed-citation></ref><ref id="dgae734-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cano</surname> &#160;<given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Fonseca Fuentes</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Corsini Campioli</surname> &#160;<given-names>C</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis</article-title><source>Chest</source>. <year>2021</year>;<volume>159</volume>(<issue>3</issue>):<fpage>1019</fpage>&#8208;<lpage>1040</lpage>.<pub-id pub-id-type="pmid">33129791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chest.2020.10.054</pub-id><pub-id pub-id-type="pmcid">PMC7598533</pub-id></mixed-citation></ref><ref id="dgae734-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perez</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jansen-Chaparro</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Saigi</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bernal-Lopez</surname> &#160;<given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Mi&#241;ambres</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gomez-Huelgas</surname> &#160;<given-names>R</given-names></string-name></person-group>. <article-title>Glucocorticoid-induced hyperglycemia</article-title>. <source>J Diabetes</source>. <year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>9</fpage>&#8208;<lpage>20</lpage>.<pub-id pub-id-type="pmid">24103089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1753-0407.12090</pub-id></mixed-citation></ref><ref id="dgae734-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruzzin</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wagman</surname> &#160;<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor</article-title>. <source>Diabetologia</source>. <year>2005</year>;<volume>48</volume>(<issue>10</issue>):<fpage>2119</fpage>&#8208;<lpage>2130</lpage>.<pub-id pub-id-type="pmid">16078016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-005-1886-0</pub-id></mixed-citation></ref><ref id="dgae734-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beaupere</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liboz</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>F&#232;ve</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Blondeau</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Guillemain</surname> &#160;<given-names>G</given-names></string-name></person-group>. <article-title>Molecular mechanisms of glucocorticoid-induced insulin resistance</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>2</issue>):<fpage>623</fpage>.<pub-id pub-id-type="pmid">33435513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22020623</pub-id><pub-id pub-id-type="pmcid">PMC7827500</pub-id></mixed-citation></ref><ref id="dgae734-B21"><label>21</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><given-names>Kim</given-names> &#160;<surname>HN</surname></string-name>, <string-name name-style="western"><given-names>Mathioudakis N. Management of glucocorticoid-induced</given-names> &#160;<surname>diabetes</surname></string-name> and/or hyperglycemia. In: <string-name name-style="western"><surname>Matfin</surname> &#160;<given-names>G</given-names></string-name></person-group>, ed. <italic toggle="yes">Endocrine and Metabolic Medical Emergencies: A Clinician's Guide</italic>. Chapter 38. Wiley-Blackwell; 2018:616-631.</mixed-citation></ref><ref id="dgae734-B22"><label>22</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathioudakis</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dungan</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Korytkowski</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><given-names>Reider J.</given-names> &#160;<surname>Steroid-Associated</surname></string-name> hyperglycemia. In: <string-name name-style="western"><surname>Draznin</surname> &#160;<given-names>B</given-names></string-name></person-group>, ed. <italic toggle="yes">Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide</italic>. Chapter 7. American Diabetes Association; 2016.</mixed-citation></ref><ref id="dgae734-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scott</surname> &#160;<given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Str&#246;mstedt</surname> &#160;<given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Granner</surname> &#160;<given-names>DK</given-names></string-name></person-group>. <article-title>Further characterization of the glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. The role of the glucocorticoid receptor-binding sites</article-title>. <source>Mol Endocrinol</source>. <year>1998</year>;<volume>12</volume>(<issue>4</issue>):<fpage>482</fpage>&#8208;<lpage>491</lpage>.<pub-id pub-id-type="pmid">9544984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/mend.12.4.0090</pub-id></mixed-citation></ref><ref id="dgae734-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Delaunay</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cintra</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids</article-title>. <source>J Clin Invest</source>. <year>1997</year>;<volume>100</volume>(<issue>8</issue>):<fpage>2094</fpage>&#8208;<lpage>2098</lpage>.<pub-id pub-id-type="pmid">9329975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI119743</pub-id><pub-id pub-id-type="pmcid">PMC508401</pub-id></mixed-citation></ref><ref id="dgae734-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matsumoto</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yamasaki</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Akazawa</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1996</year>;<volume>81</volume>(<issue>7</issue>):<fpage>2621</fpage>&#8208;<lpage>2626</lpage>.<pub-id pub-id-type="pmid">8675587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.81.7.8675587</pub-id></mixed-citation></ref><ref id="dgae734-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Raalte</surname> &#160;<given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Nofrate</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bunck</surname> &#160;<given-names>MC</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men</article-title>. <source>Eur J Endocrinol</source>. <year>2010</year>;<volume>162</volume>(<issue>4</issue>):<fpage>729</fpage>&#8208;<lpage>735</lpage>.<pub-id pub-id-type="pmid">20124412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-09-1034</pub-id></mixed-citation></ref><ref id="dgae734-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuo</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McQueen</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>JC</given-names></string-name></person-group>. <article-title>Regulation of glucose homeostasis by glucocorticoids</article-title>. <source>Adv Exp Med Biol</source>. <year>2015</year>;<volume>872</volume>:<fpage>99</fpage>&#8208;<lpage>126</lpage>.<pub-id pub-id-type="pmid">26215992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2895-8_5</pub-id><pub-id pub-id-type="pmcid">PMC6185996</pub-id></mixed-citation></ref><ref id="dgae734-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bajaj</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Zale</surname> &#160;<given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Morgenlander</surname> &#160;<given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Abusamaan</surname> &#160;<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Mathioudakis</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Insulin dosing and glycemic outcomes among steroid-treated hospitalized patients</article-title>. <source>Endocr Pract</source>. <year>2022</year>;<volume>28</volume>(<issue>8</issue>):<fpage>774</fpage>&#8208;<lpage>779</lpage>.<pub-id pub-id-type="pmid">35550182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eprac.2022.05.002</pub-id></mixed-citation></ref><ref id="dgae734-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klonoff</surname> &#160;<given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Messler</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Umpierrez</surname> &#160;<given-names>GE</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>(<issue>2</issue>):<fpage>578</fpage>&#8208;<lpage>585</lpage>.<pub-id pub-id-type="pmid">33323475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc20-1857</pub-id><pub-id pub-id-type="pmcid">PMC7818335</pub-id></mixed-citation></ref><ref id="dgae734-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lombardi</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schechter</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tomer</surname> &#160;<given-names>Y</given-names></string-name></person-group>. <article-title>In-Hospital hyperglycemia is associated with worse outcomes in patients admitted with COVID-19</article-title>. <source>Diabetes Care</source>. <year>2022</year>;<volume>45</volume>(<issue>11</issue>):<fpage>2683</fpage>&#8208;<lpage>2688</lpage>.<pub-id pub-id-type="pmid">36041197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc22-0708</pub-id><pub-id pub-id-type="pmcid">PMC9679263</pub-id></mixed-citation></ref><ref id="dgae734-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garibaldi</surname> &#160;<given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Fiksel</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Muschelli</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Patient trajectories among persons hospitalized for COVID-19: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2021</year>;<volume>174</volume>(<issue>1</issue>):<fpage>33</fpage>&#8208;<lpage>41</lpage>.<pub-id pub-id-type="pmid">32960645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-3905</pub-id><pub-id pub-id-type="pmcid">PMC7530643</pub-id></mixed-citation></ref><ref id="dgae734-B32"><label>32</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathioudakis</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Supplemental Materials: Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients with Diabetes: A Retrospective Cohort Study, Mendeley Data, V1</article-title>. <year>2024</year>. Accessed October 21, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.mendeley.com/datasets/wynt5r2rzn/1" ext-link-type="uri">https://data.mendeley.com/datasets/wynt5r2rzn/1</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgae734</pub-id><pub-id pub-id-type="pmcid">PMC12187182</pub-id><pub-id pub-id-type="pmid">39418352</pub-id></mixed-citation></ref><ref id="dgae734-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garibaldi</surname> &#160;<given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname> &#160;<given-names>ML</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>3</issue>):<fpage>e213071</fpage>.<pub-id pub-id-type="pmid">33760094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.3071</pub-id><pub-id pub-id-type="pmcid">PMC7991975</pub-id></mixed-citation></ref><ref id="dgae734-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deng</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ido</surname> &#160;<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Long</surname> &#160;<given-names>Q</given-names></string-name></person-group>. <article-title>Multiple imputation for general missing data patterns in the presence of high-dimensional data</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>21689</fpage>.<pub-id pub-id-type="pmid">26868061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep21689</pub-id><pub-id pub-id-type="pmcid">PMC4751511</pub-id></mixed-citation></ref><ref id="dgae734-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kumar</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Arora</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname> &#160;<given-names>P</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis</article-title>. <source>Diabetes Metab Syndr</source>. <year>2020</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>&#8208;<lpage>545</lpage>.<pub-id pub-id-type="pmid">32408118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dsx.2020.04.044</pub-id><pub-id pub-id-type="pmcid">PMC7200339</pub-id></mixed-citation></ref><ref id="dgae734-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eng</surname> &#160;<given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Distaso</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Durreshahwar</surname> &#160;<given-names>H</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2022</year>;<volume>24</volume>(<issue>7</issue>):<fpage>1385</fpage>&#8208;<lpage>1389</lpage>.<pub-id pub-id-type="pmid">35293117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.14692</pub-id><pub-id pub-id-type="pmcid">PMC9111414</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>